((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)
路透10月3日 - 艾伯维 周四下调了对2024年调整后利润的预期，理由是8200万美元的里程碑以及与收购相关的研发费用的影响 。
一份监管文件显示，该制药公司预计年度调整后每股利润在10.67美元至10.87美元之间，而之前的预测为每股10.71美元至10.91美元。
根据 LSEG 的估计，分析师的预期为每股 10.88 美元。
艾伯维还将第三季度调整后每股利润预期 从之前的2.92美元至2.96美元下调至2.88美元至2.92美元。
该公司表示，本季度与合作、许可协议和其他资产收购相关的支出为8200万美元。
艾伯维定于10月30日公布第三季度财报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.